ישראל -
עברית -
Ministry of Health
drager medical products
עמוס גזית בע"מ - רופא - מוצרי חב' דרגר לפי קבוצות חלוקה : הנשמה , הרדמה , ציוד לטיפול בילודים , מוניטורים. כל הקבוצות כוללות נלווים.
ישראל -
עברית -
Ministry of Health
programming system for aimd (rx5000)
קיור מדיקל אנד טכניקל סופלאי - רופא - לתיכנות של קוצבי לב
ישראל -
עברית -
Ministry of Health
interactive computerized programfor ombl
"סיגמא בי.די בע""מ" - מומחה - טיפול לא פולשני לעין עצלה )aipoylbmo( בעזרת תוכנת מחשב אינטראקטיבית
ישראל -
עברית -
Ministry of Health
interactive computerized programfor ombl
"טלשיר גיא טכנולוגיות רפואיות בע""מ" - מומחה - טיפול לא פולשני לעין עצלה )aipoylbmo( בעזרת תוכנת מחשב אינטראקטיבית + אפליקציות נוספות לטיפול בליקויי ראיה
ישראל -
עברית -
Ministry of Health
lyophilized micro-organizms &slide prepprations for microbiology labs and qa programs
כמיטק - מומחה - מיקרואורגניזמים ופלטות מוכנות לשימוש מעבדות מיקרוביולוגיות ולאבטחת איכות
ישראל -
עברית -
Ministry of Health
hearttrend program
lev el ltd. - רופא - תוכנה למדידת השתנות קצב הלב
ישראל -
עברית -
Ministry of Health
בינוקריט 1000 יחבל 0.5 מל
novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 1000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob
ישראל -
עברית -
Ministry of Health
בינוקריט 2000 יחבל 1 מל
novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 2000 iu / 1 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob
ישראל -
עברית -
Ministry of Health
בינוקריט 30000 יחבל 0.75 מל
novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 30000 iu / 0.75 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob